AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7745516 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 224
Study 2044332 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 10 mg intravenously
Number of subjects: 5
Study 2044332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 7016300 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG treatment (120 mg intravesically and 5 mg percutaneously, six weekly administrations)
Number of subjects: 51
Study 7016300 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 7016300 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG treatment
Number of subjects: 51
Study 30712725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy
Number of subjects: 120
Study 30712725 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 120
Study 30712725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine spray
Number of subjects: 120
Study 30712725 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 27683798 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab every 4 weeks
Number of subjects: 100
Study 27683798 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dosing frequency from every 8 weeks to every 4 weeks
Number of subjects: 100
Study 27683798 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 100
Study 26072416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexa-Vec (JX-594) administered by intratumoral injection at a dose of 1 × 10(8) pfu
Number of subjects: 0
Study 26072416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexa-Vec (JX-594) administered by intratumoral injection at a dose of 1 × 10(9) pfu
Number of subjects: 0
Study 26072416 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22021066 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination with cyclophosphamide
Number of subjects: 11
Study 22021066 — intervention group
Group type: COMPARATOR
Intervention: Dendritic cell vaccination without cyclophosphamide (control)
Number of subjects: 11
Study 22021066 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination
Number of subjects: 11
Study 20004781 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1744 (2 microg)
Number of subjects: 31
Study 20004781 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1744 (5 microg)
Number of subjects: 31
Study 20004781 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1744 (10 microg)
Number of subjects: 31
Study 20004781 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1744 (20 microg)
Number of subjects: 31
Study 20004781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 16613765 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (HCD) - 4200 kcal/24 h
Number of subjects: 32
Study 16613765 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (HD) - 3200 kcal/24 h
Number of subjects: 32
Study 12663290 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (1250 mL/d, 5 cups each containing 2 g tea leaves in 250 mL boiled water)
Number of subjects: 22
Study 12663290 — intervention group
Group type: COMPARATOR
Intervention: Hot water (1250 mL/d)
Number of subjects: 22
Study 12663290 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 22
Study 10859453 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine plus MLT (20 mg/day orally in the evening)
Number of subjects: 30
Study 10859453 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 30
Study 10859453 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine plus MLT
Number of subjects: 30
Study 8889853 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncemented THA
Number of subjects: 53
Study 8889853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented THA
Number of subjects: 53
Study 8889853 — intervention group
Group type: COMPARATOR
Intervention: Control sides (not undergoing THA)
Number of subjects: 53
Study 10895734 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient age 84 years
Number of subjects: 159
Study 10895734 — intervention group
Group type: COMPARATOR
Intervention: Patient age 65 years
Number of subjects: 159
Study 10895734 — intervention group
Group type: COMPARATOR
Intervention: Patient age 44 years
Number of subjects: 159
Study 6360110 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% acyclovir ointment five times a day in combination with alpha-interferon (30 million IU/mL)
Number of subjects: 59
Study 6360110 — intervention group
Group type: COMPARATOR
Intervention: 3% acyclovir ointment five times a day
Number of subjects: 59
Study 31672145 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTION Respecting Choices (RC) ACP conversation
Number of subjects: 39
Study 30327351 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 0
Study 30327351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27923864 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Need Support (ENS; eight contacts over 12 months)
Number of subjects: 0
Study 27923864 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm Reduction (HR; eight contacts over 12 months with medication use)
Number of subjects: 0
Study 27923864 — intervention group
Group type: COMPARATOR
Intervention: Intensive Treatment (IT; six contacts over 6 months)
Number of subjects: 0
Study 24042068 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 106
Study 24042068 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical rehabilitation
Number of subjects: 106
Study 24042068 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Number of subjects: 106
Study 24042068 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 106
Study 22908692 — intervention group
Group type: EXPERIMENTAL
Intervention: FeSO₄
Number of subjects: 29
Study 22908692 — intervention group
Group type: EXPERIMENTAL
Intervention: NaFeEDTA
Number of subjects: 29
Study 22908692 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 mixture of FeSO₄ and NaFeEDTA
Number of subjects: 29
Study 22908692 — intervention group
Group type: COMPARATOR
Intervention: FeSO₄ (control in study 2)
Number of subjects: 29
Study 20524974 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU; 1,000 mg IM at baseline, and after 6 and 18 weeks)
Number of subjects: 184
Study 20524974 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 184
Study 17907030 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-head (OTH) CPR
Number of subjects: 8
Study 17907030 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR with bag-valve-mask (BVM) ventilation
Number of subjects: 8
Study 15531561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic challenge (15% O(2), 85% N(2)) during functional MRI assessment.
Number of subjects: 14
Study 15531561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic challenge (15% O(2), 85% N(2)) in CCHS patients.
Number of subjects: 14
Study 15531561 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic challenge (15% O(2), 85% N(2)) in controls.
Number of subjects: 14
Study 12002960 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-adaptive test with manipulated difficulty of initial and subsequent items
Number of subjects: 0
Study 12002960 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback consistent with perceptions of performance
Number of subjects: 0
Study 12002960 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor changes to the design of an adaptive test
Number of subjects: 0
Study 10426171 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA
Number of subjects: 32
Study 10426171 — intervention group
Group type: COMPARATOR
Intervention: Preterm
Number of subjects: 32
Study 7823995 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily trial of spontaneous breathing
Number of subjects: 546
Study 7823995 — intervention group
Group type: COMPARATOR
Intervention: Intermittent mandatory ventilation
Number of subjects: 546
Study 7823995 — intervention group
Group type: COMPARATOR
Intervention: Pressure-support ventilation
Number of subjects: 546
Study 7823995 — intervention group
Group type: COMPARATOR
Intervention: Intermittent trials of spontaneous breathing
Number of subjects: 546
Study 2079566 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon 5 million units per day with prednisone withdrawal (Group A)
Number of subjects: 57
Study 2079566 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon 1 million units (Group C)
Number of subjects: 57
Study 2079566 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo followed by interferon 5 million units (Group B)
Number of subjects: 57
Study 2079566 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon 5 million units with prednisone withdrawal (Group A)
Number of subjects: 57
Study 2079566 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (Group D)
Number of subjects: 57
Study 2079566 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment responders (Groups A, B, C)
Number of subjects: 57
Study 2079566 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders from groups A and B
Number of subjects: 57
Study 90270 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg BAY g 5421 before a 50 g sucrose meal
Number of subjects: 10
Study 90270 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotopic method for gastric emptying
Number of subjects: 10
Study 31863251 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocardial LAA isolation during RFA for AF
Number of subjects: 182
Study 31863251 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA exclusion with LARIAT device followed by RFA for AF
Number of subjects: 182
Study 31615549 — intervention group
Group type: EXPERIMENTAL
Intervention: myTAPS screening tool
Number of subjects: 2000
Study 29354671 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium HandiHaler®
Number of subjects: 219
Study 29354671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 25712847 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest tube removal on the 2nd day after operation (Experimental Group - EG)
Number of subjects: 154
Study 25712847 — intervention group
Group type: COMPARATOR
Intervention: Chest tube removal when drainage volume <100 ml/day (Control Group - CG)
Number of subjects: 154
Study 25712847 — intervention group
Group type: COMPARATOR
Intervention: Open thoracic lobectomy (OG)
Number of subjects: 154
Study 25712847 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (EG, CG, OG)
Number of subjects: 154
Study 22310245 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) at constant intensity
Number of subjects: 11
Study 22310245 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) at gradually increasing intensity
Number of subjects: 11
Study 22310245 — intervention group
Group type: COMPARATOR
Intervention: Both conditions (constant and gradually increasing intensity)
Number of subjects: 11
Study 21692283 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 91
Study 21692283 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 91
Study 21692283 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy of electroacupuncture and acupoint injection
Number of subjects: 91
Study 20218480 — intervention group
Group type: COMPARATOR
Intervention: Dynamic exercise rehabilitation programme (CER)
Number of subjects: 30
Study 20218480 — intervention group
Group type: COMPARATOR
Intervention: Upper body strength training programme (UBST)
Number of subjects: 30
Study 16462284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pocket AOM card
Number of subjects: 0
Study 16462284 — intervention group
Group type: EXPERIMENTAL
Intervention: Total AOM card severity
Number of subjects: 0
Study 12707868 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) procedure
Number of subjects: 116
Study 12707868 — intervention group
Group type: COMPARATOR
Intervention: Modified Burch colposuspension
Number of subjects: 116
Study 10731289 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin and abciximab administration during percutaneous coronary intervention
Number of subjects: 0
Study 10731289 — intervention group
Group type: COMPARATOR
Intervention: Abciximab administration
Number of subjects: 0
Study 10731289 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0
Study 8613615 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologically guided focal ablation technique (Group I)
Number of subjects: 60
Study 8613615 — intervention group
Group type: COMPARATOR
Intervention: Linear ablation technique (Group II)
Number of subjects: 60
Study 1571752 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300-600 mg/day)
Number of subjects: 129
Study 1571752 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (100-200 mg/day)
Number of subjects: 129
Study 1571752 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 129
Study 1571752 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 129
Study 3883503 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 40 mg orally, four times daily
Number of subjects: 124
Study 3883503 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 10 mg orally twice daily
Number of subjects: 124
Study 3883503 — intervention group
Group type: COMPARATOR
Intervention: Crossover from megestrol acetate to tamoxifen
Number of subjects: 124
Study 3883503 — intervention group
Group type: COMPARATOR
Intervention: Crossover from tamoxifen to megestrol acetate
Number of subjects: 124
Study 3883503 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 124
Study 3883503 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 124
Study 29767281 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance of gender inequitable norms
Number of subjects: 919
Study 29767281 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance of IPV
Number of subjects: 919
Study 29767281 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher self-esteem
Number of subjects: 919
Study 29874228 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-site/1-week regimen (PCECV)
Number of subjects: 885
Study 29874228 — intervention group
Group type: COMPARATOR
Intervention: 2-site/TRC regimen (PCECV)
Number of subjects: 885
Study 29874228 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-site/1-week regimen with HRIG
Number of subjects: 885
Study 29874228 — intervention group
Group type: COMPARATOR
Intervention: 2-site/TRC regimen with HRIG
Number of subjects: 885
Study 29874228 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-site/1-week regimen
Number of subjects: 885
Study 29874228 — intervention group
Group type: COMPARATOR
Intervention: 2-site/TRC regimen
Number of subjects: 885
Study 25486294 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine (BA) supplementation (3.4 g)
Number of subjects: 16
Study 25486294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL; 5 g maltodextrin)
Number of subjects: 16
Study 25486294 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BA and PL)
Number of subjects: 16
Study 24571184 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration Training Group (VTG)
Number of subjects: 20
Study 24571184 — intervention group
Group type: COMPARATOR
Intervention: Conventional Training Group (CTG)
Number of subjects: 20
Study 22963388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oriental Medicine Music Therapy (OMMT)
Number of subjects: 48
Study 22963388 — intervention group
Group type: COMPARATOR
Intervention: Control Music Therapy (CMT)
Number of subjects: 48
Study 21054464 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, Amoxicillin, and Clarithromycin (OAC)
Number of subjects: 240
Study 21054464 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole, Amoxicillin, and Clarithromycin (RAC)
Number of subjects: 240
Study 21054464 — intervention group
Group type: COMPARATOR
Intervention: IL-1RN and IL-1B genotype groups
Number of subjects: 240
Study 18020933 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 56
Study 18020933 — intervention group
Group type: EXPERIMENTAL
Intervention: Other psychosocial interventions
Number of subjects: 56
Study 18020933 — intervention group
Group type: COMPARATOR
Intervention: Nonpsychologist-led interventions
Number of subjects: 56
Study 18020933 — intervention group
Group type: COMPARATOR
Intervention: Samples consisting of only BC patients
Number of subjects: 56
Study 16344384 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release (SR) TAXUS stents
Number of subjects: 161
Study 16344384 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-release (MR) TAXUS stents
Number of subjects: 161
Study 16344384 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal control stents (BMS)
Number of subjects: 161
Study 12160664 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (up to 600 mg daily)
Number of subjects: 59
Study 12160664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 11811503 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 16
Study 11811503 — intervention group
Group type: EXPERIMENTAL
Intervention: Osseous surgery (OS)
Number of subjects: 16
Study 11811503 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Widman (MW)
Number of subjects: 16
Study 9622282 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg o.d.)
Number of subjects: 15
Study 7933456 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 9
Study 7933456 — intervention group
Group type: COMPARATOR
Intervention: Moduretic
Number of subjects: 9
Study 7933456 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 9
Study 3063782 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 14
Study 3063782 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg)
Number of subjects: 14
Study 29621293 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (1.5 mg subcutaneous injection)
Number of subjects: 35
Study 29621293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 27164988 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhiatal approach and D2 total gastrectomy after neoadjuvant chemotherapy (NAC) for AEG patients
Number of subjects: 83
Study 27164988 — intervention group
Group type: COMPARATOR
Intervention: D2 gastrectomy after neoadjuvant chemotherapy (NAC) for non-AEG patients
Number of subjects: 83
Study 27164988 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhiatal approach and D2 total gastrectomy after NAC
Number of subjects: 83
Study 27164988 — intervention group
Group type: COMPARATOR
Intervention: D2 gastrectomy after NAC
Number of subjects: 83
Study 26222764 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (NST) including neoadjuvant paclitaxel ± carboplatin ± bevacizumab followed by doxorubicin plus cyclophosphamide ± bevacizumab
Number of subjects: 404
Study 26222764 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (NST)
Number of subjects: 404
Study 24007766 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred education including device technique
Number of subjects: 114
Study 24007766 — intervention group
Group type: COMPARATOR
Intervention: Written information-only education
Number of subjects: 114
Study 21048092 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (0.5 μg · kg(‐1) · min(‐1))
Number of subjects: 124
Study 21048092 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (Control)
Number of subjects: 124
Study 19032126 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled asthma (81.9% of patients)
Number of subjects: 1009
Study 19032126 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy detected in patients
Number of subjects: 1009
Study 19032126 — intervention group
Group type: EXPERIMENTAL
Intervention: Early onset of asthma
Number of subjects: 1009
Study 19032126 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic symptoms (allergic rhinitis)
Number of subjects: 1009
Study 19032126 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic symptoms (rhinosinusitis)
Number of subjects: 1009
Study 19032126 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of medications
Number of subjects: 1009
Study 17010742 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/L methoxsalen
Number of subjects: 46
Study 17010742 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/L methoxsalen
Number of subjects: 46
Study 14740594 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bupivacaine 0.1% mixed with 20 micrograms fentanyl
Number of subjects: 80
Study 14740594 — intervention group
Group type: COMPARATOR
Intervention: 5 mg bupivacaine 0.1%
Number of subjects: 80
Study 10811540 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 800 mg/day
Number of subjects: 0
Study 10811540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8623956 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0% sevoflurane
Number of subjects: 50
Study 8623956 — intervention group
Group type: COMPARATOR
Intervention: 5.0% isoflurane
Number of subjects: 50
Study 1441877 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 2.2% lidocaine hydrocarbonate with 5 micrograms.ml‐1 epinephrine (Group CO2 = 13 patients)
Number of subjects: 26
Study 1441877 — intervention group
Group type: COMPARATOR
Intervention: 20 ml of 2% lidocaine hydrochloride with 5 micrograms.ml‐1 epinephrine (HCl group)
Number of subjects: 26
Study 30092657 — intervention group
Group type: EXPERIMENTAL
Intervention: Make the Connection (MTC) parenting programme
Number of subjects: 180
Study 30092657 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 180
Study 30092657 — intervention group
Group type: COMPARATOR
Intervention: Time (regardless of programme participation)
Number of subjects: 180